Active, not recruitingPhase 3NCT03299426
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
Studying Typhoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Maryland, Baltimore
- Principal Investigator
- Matthew Laurens, MDUniversity of Maryland, Baltimore
- Intervention
- Vi-Typhoid Conjugate Vaccine (Vi-TCV)(biological)
- Enrollment
- 30000 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2018 – 2025
Study locations (1)
- Malawi Liverpool Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital College of Medicine, Blantyre, Malawi
Collaborators
Bill and Melinda Gates Foundation · Malawi-Liverpool-Wellcome Trust Clinical Research Programme · University College, London · University of Malawi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03299426 on ClinicalTrials.govOther trials for Typhoid
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950Induction of Gut Permeability by an Oral VaccineUSDA, Western Human Nutrition Research Center
- ACTIVE NOT RECRUITINGPHASE4NCT03970304CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated AdultsUniversity of Maryland, Baltimore